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Background: Data have highlighted the potential bias introduced by withdrawal of inhaled 
corticosteroids at randomization in chronic obstructive pulmonary disease trials examining 
inhaled corticosteroids. Analyses were conducted to determine whether this was true of inhaled 
anticholinergic withdrawal in tiotropium trials.
Methods: A pooled analysis of randomized, double-blind, placebo-controlled, parallel-group 
tiotropium trials of at least six months’ duration was performed. Trials had similar inclusion 
and exclusion criteria. Exacerbation definition was standardized. Patients were divided into two 
groups, ie, D (anticholinergics discontinued at randomization, previously prescribed) and ND 
(anticholinergics not discontinued, not previously prescribed).
Results: Demographics were balanced between the D (n = 5846) and ND (n = 6317) groups, 
except for higher cumulative smoking (56 pack-years versus 48 pack-years), lower forced 
expiratory volume in one second (FEV
1
)/forced vital capacity (43% versus 48%), and lower 
baseline FEV
1
 (35.8% predicted versus 42.4% predicted) in the D group. In both groups, 
tiotropium reduced the risk for an exacerbation (hazard ratio [HR] = 0.83, P , 0.0001 [D] 
versus 0.79, P , 0.0001 [ND]) and a hospitalized exacerbation (HR = 0.85, P = 0.0467 versus 
0.79, P = 0.0094). Tiotropium reduced the number of exacerbations per patient-year (rate ratio 
[RR] = 0.82, P , 0.0001 [D] versus RR = 0.80, P , 0.0001 [ND]) and associated hospitalizations 
per patient-year (RR = 0.88, P = 0.015 [D] versus RR = 0.74, P , 0.0001 [ND]).
Conclusion: Tiotropium reduced exacerbations in patients who did and did not have 
anticholinergics discontinued upon randomization in clinical trials.
Keywords: chronic obstructive pulmonary disease, clinical trials, exacerbations, inhaled 
anticholinergics, tiotropium
Introduction
The randomized, controlled clinical trial is an attempt to minimize bias introduced 
by the knowledge of treatment allocation and, thereby, come to reliable conclusions 
regarding the hypothesis tested. Many interventional, randomized, controlled clinical 
trials need to assume that randomization distributes baseline characteristics equally, 
and that patients enter the clinical trial in a stable state. However, inclusion and 
exclusion criteria can lead to biases which are not necessarily anticipated. When 
the intervention examined is already used by any portion of the population, patients 
need to be  withdrawn from the intervention. While this may be drug-specific, the 
withdrawal of previously prescribed medication is often based on the pharmacologic 
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class or mechanism of action of the study drug. Most trials 
assume that patients are medically stable at randomization, 
but withdrawal of medication may worsen the underlying 
disease.
Three groups of investigators1–3 have highlighted 
issues introduced by withdrawal of inhaled corticosteroids 
at randomization into clinical trials examining inhaled 
corticosteroids in chronic obstructive pulmonary disease 
(COPD). Suissa et al1 concluded that the effects of withdrawal 
of medication cannot be assumed to be the same as addition 
of the medication. While the authors demonstrated this to be 
the case with inhaled corticosteroids, they considered whether 
withdrawal of other COPD medication, including inhaled 
anticholinergics, may lead to a similar phenomenon.
Our access to the tiotropium clinical trial database 
allowed us to undertake a thorough analysis of whether 
withdrawal of inhaled anticholinergics influenced the results 
observed with tiotropium on reducing COPD exacerbations. 
To our knowledge, this is the first analysis that has examined 
the issue of medication withdrawal at the onset of clinical 
trials of anticholinergic therapy.
Methods
study design
A pooled analysis of 10 randomized, double-blind, placebo-
controlled, parallel-group studies of at least six months’ 
duration with tiotropium 18 µg administered once daily 
via the HandiHaler® device (Boehringer Ingelheim GmbH, 
Ingelheim, Germany) was performed (trial numbers 
205.114/117,4 205.115/128,5 205.130,6 205.137,6 205.266,7 
205.270,8 205.235 [Understanding Potential Long-term 
Impacts on Function with Tiotropium (UPLIFT®)],9 
205.214,10 205.256,11 205.25912), as shown in Figure 1. One 
study was longer than one year (UPLIFT, which included 
5993 COPD patients followed over four years).9 All trials 
included evaluation of exacerbations and spirometry. Seven 
trials (trial numbers 205.114/117, 205.115/128, 205.130, 
205.137, 205.235 [UPLIFT], 205.256, and 205.259) 
included measurement using the St George’s Respiratory 
Questionnaire (SGRQ).13 All trial protocols were approved 
by independent ethics committees, and patients in all trials 
provided written informed consent. The trials were conducted 
in accordance with the Declaration of Helsinki.
study population
All trials included in this pooled analysis had common entry 
criteria, ie, a clinical diagnosis of COPD, age .40 years, 
smoking history $10 pack-years, postbronchodilator forced 
expiratory volume in one second (FEV
1
)/forced vital capacity 
ratio ,0.7, and FEV
1
 either #65% or #70% of predicted. 
Whilst the patients participating in these studies were clas-
sified as to the severity of their COPD on the basis of post-
bronchodilator FEV
1
 measurements, the data reported in this 
paper were prebronchodilator values.
Exclusion criteria included a history of asthma, the need 
for continuous supplemental oxygen, a COPD exacerbation 
within the previous six weeks, recent myocardial infarction 
or hospitalization for congestive heart failure, other unstable 
medical conditions that may preclude participation or inter-
pretation of the results, and use of systemic corticosteroids 
in doses greater than the equivalent of prednisone 10 mg 
daily. Responsiveness to bronchodilator therapy was not 
measured consistently between the clinical trials. Therefore, 
these measurements were not included in the data analysis. 
Consistent clinical criteria were applied to exclude patients 
with asthma. We believe that this is the most dependable 
method for excluding patients with asthma, given that it is 
now well known that bronchodilator responsiveness does not 
discriminate between asthma and COPD.
COPD exacerbations
All trials included data on COPD exacerbations. The 
following standardized definition was used to characterize 
COPD exacerbations in the current analysis: “An exacerbation 
is def ined by two or more (increased or new-onset) 
10 randomized, double-blind,
placebo-controlled, parallel-group trials of
tiotropium (18 µg, OD, via HandiHaler® )
of ≥6 months’ duration identified in
Boehringer Ingelheim trial database
Total pooled patients:
Tiotropium, n = 6295
Placebo, n = 5868
Tiotropium
AC discontinued, n = 3063
AC not discontinued, n = 3232
Placebo
AC discontinued, n = 2783
AC not discontinued, n = 3085
Figure 1 study design overview. Patients from 10 pooled trials, receiving tiotropium 
or placebo, were analyzed according to whether they were receiving inhaled 
anticholinergics prior to participation in the trial, hence discontinued at trial start, 
or if they were not receiving inhaled anticholinergics at trial initiation, therefore did 
not discontinue (not discontinued).
Abbreviations: AC, anticholinergic; OD, once daily.
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respiratory symptoms such as cough, sputum, wheezing, 
dyspnea, or chest tightness, lasting at least three days, and 
requiring treatment with antibiotics and/or steroids, and/or 
hospitalization”.14
Patients were grouped according to inhaled anticholin-
ergic discontinuation, ie, D (anticholinergic prescribed prior 
to participation and discontinued at randomization) and 
ND (anticholinergic not prescribed prior to participation and 
therefore not discontinued).
Data analysis
Kaplan–Meier curves of the probability of no exacerbation 
and no hospitalization due to exacerbations were displayed. 
Cox regression was used to compute hazard ratios (HR) of 
tiotropium to placebo using trial as stratum.
The analysis of number of exacerbations and number of 
hospitalizations due to exacerbations was performed using 
Poisson regression, with correction for treatment exposure 
and overdispersion with terms for treatment subgroup and 
treatment by subgroup interaction. The effects of tiotropium 
or placebo on the SGRQ total score in trials where the SGRQ 
was measured was examined according to whether or not 
subjects discontinued anticholinergic therapy. These data 
are displayed as mean (standard error of the mean) values 
and have been compared with unpaired t-tests.
Results
Demographics
Of the 12,163 patients who were randomized into these 
clinical trials, 5846 were receiving inhaled anticholinergics 
that were discontinued at randomization (D group) and 6317 
were not receiving inhaled anticholinergics at the time of 
randomization (ND group). The inhaled anticholinergic was 
ipratropium bromide in the vast majority of patients who 
were already receiving inhaled anticholinergics. At time of 
initiation of all of the aforementioned trials, tiotropium was 
not available in the respective countries where the studies 
were performed. Approval of tiotropium occurred in several 
of the trials during the recruitment phase. There were a few 
patients who did receive tiotropium prior to randomization 
(109 of 12,164 patients), with 49 being withdrawn from 
tiotropium. The baseline characteristics of these patients 
are shown in Table 1. For group D, the mean age was 
66.1 years compared with 64.5 years for the ND group. 
Gender distribution was similar across groups. Patients who 
had previously been prescribed anticholinergics had lower 
Table1 Baseline characteristics* of patients according to treatment allocation (tiotropium or placebo)
Discontinued Not discontinued
Placebo Tiotropium Total Placebo Tiotropium Total
number of patients (%) 2783 (100.0) 3063 (100.0) 5846 (100.0) 3085 (100.0) 3232 (100.0) 6317 (100.0)
Age, years 66.1 (8.6) 66.1 (8.4) 66.1 (8.5) 64.6 (9.0) 64.4 (8.8) 4.5 (8.9)
gender, n (%) 
 Female 577 (20.7) 623 (20.3) 1200 (20.5) 712 (23.1) 762 (23.6) 1474 (23.3)
 Male 2206 (79.3) 2440 (79.7) 4646 (79.5) 2373 (76.9) 2470 (76.4) 4843 (76.7)
smoking history, n (%)
 exsmoker 1972 (70.9) 2176 (71.0) 4148 (71.0) 2084 (67.6) 2193 (67.9) 4277 (67.7)
 never smoked 1 (0.0) 0 (0.0) 1 (0.0) 1 (0.0) 0 (0.0) 1 (0.0)
 smoker 809 (29.1) 887 (29.0) 1696 (29.0) 1000 (32.4) 1038 (32.1) 2038 (32.3)
 Missing 1 (0.0) 0 (0.0) 1 (0.0) 0 (0.0) 1 (0.0) 1 (0.0)
smoking history, pack-years 55.6 (32.3) 55.5 (30.9) 55.6 (31.6) 47.6 (27.5) 48.8 (26.7) 48.2 (26.6)
BMI 26.3 (5.5) 26.4 (5.5) 26.4 (5.5) 26.2 (5.3) 26.3 (5.3) 26.2 (5.3)
FeV1, % predicted
† 36.0 (12.4) 35.7 (12.3) 35.8 (12.4) 42.0 (12.6) 42.7 (12.8) 42.3 (12.7)
FeV1/FVC
† 0.43 (0.11) 0.43 (0.11) 0.43 (0.11) 0.47 (0.12) 0.48 (0.12) 0.48 (0.12)
gOLD stage, n (%)
  I 1 (0.0) 0 (0.0) 1 (0.0) 1 (0.0) 7 (0.2) 8 (0.1)
  II 436 (15.7) 444 (14.5) 880 (15.1) 873 (28.3) 964 (29.8) 1837 (29.1)
  III 1351 (48.5) 1509 (49.3) 2860 (48.9) 1614 (52.3) 1662 (51.4) 3276 (51.9)
  IV 966 (34.7) 1077 ( 35.2) 2043 ( 34.9) 554 (18.0) 548 (17.0) 1102 (17.4)
  Missing 29 (1.0) 33 (1.1) 62 (1.1) 43 (1.4) 51 (1.6) 94 (1.5)
 receiving systemic corticosteroids, n (%) 295 (10.6) 283 (9.2) 578 (9.9) 137 (4.4) 145 (4.5) 282 (4.5)
Notes: *Mean (SD) unless otherwise specified. No BMI data available for study 205.214 because weights were not collected; †prebronchodilator values. gOLD based on 
prebronchodilator values: stage I = mild (FeV1 $ 80% predicted); stage II = moderate (FeV1 , 80% to $50% predicted); stage III = severe (FeV1 , 50% to $30% predicted); 
stage IV = very severe (FeV1 , 30% predicted). “not discontinued” means either “not discontinued from anticholinergics” or “never took anticholinergics”.
Abbreviations: BMI, body mass index; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; gOLD, global Initiative for Chronic Obstructive Lung 
Disease; sD, standard deviation.
International Journal of COPD 2011:6submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
272
Cooper et al
lung function and longer smoking histories. Overall, within 
the D and ND groups, the treatment subgroups (tiotropium 
and placebo) were reasonably well balanced with respect to 
their baseline characteristics.
exacerbations
There was a significantly reduced risk of an exacerbation in 
patients receiving tiotropium compared with those receiving 
placebo in the D group (HR [95% confidence interval 
(CI)] = 0.83 [0.77–0.90]) and in the ND groups (HR [95% 
CI] = 0.79 [0.73–0.85]). Similar findings were observed for 
exacerbations leading to hospitalizations with an HR (95% 
CI) of 0.85 (0.73–1.00) in the D group and 0.79 (0.65–0.94) 
in the ND group. Tiotropium delayed the time to first 
exacerbation and first hospitalized exacerbation in both the 
D and ND groups, as observed in the cumulative incidence 
displays (Figures 2 and 3).
The number of patients having at least one exacerbation 
and at least one exacerbation leading to hospitalization was 
reduced with tiotropium relative to placebo in both D and 
ND groups, as reflected by lower rate ratios (Tables 2 and 3). 
Furthermore, these effects were similar for patients in both 
D and ND groups.
st. george’s respiratory questionnaire
For the D group, the mean (standard error) total SGRQ 
score at six months was improved with tiotropium (41.4 
[0.31]) relative to those receiving placebo (44.7 [0.34], 
difference = 3.33 [0.40], P , 0.0001). For the ND group, 
the total scores were also improved with tiotropium versus 
placebo (40.3 compared with 43.1, difference = 2.78, 
P , 0.0001).
Discussion
The pooled analysis of 10 randomized, double-blind, 
placebo-controlled clinical trials involving 12,163 patients 
with COPD demonstrates that tiotropium was effective in 
reducing exacerbations in patients who did and also those 
who did not have inhaled anticholinergics discontinued upon 
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Figure 2 Cumulative incidence estimate (Kaplan–Meier) of the probability of a 
COPD exacerbation. Tiotropium delayed time to first exacerbation A) in patients 
who discontinued inhaled anticholinergics at randomization; and B) in patients 
who were not prescribed inhaled anticholinergics prior to randomization (ie, no 
discontinuation of inhaled anticholinergics).
Abbreviation: COPD, chronic obstructive pulmonary disease.
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Figure 3 Cumulative incidence estimate (Kaplan–Meier) of the probability of 
a COPD exacerbation leading to a hospitalization. Tiotropium reduced the 
probability of experiencing an exacerbation A) in patients who discontinued inhaled 
anticholinergics at randomization; and B) in patients who were not prescribed 
inhaled anticholinergics prior to randomization (ie, no discontinuation of inhaled 
anticholinergics).
Abbreviation: COPD, chronic obstructive pulmonary disease.
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randomization. In patients who discontinued anticholinergic 
therapy, there was a 17% risk reduction for an exacerbation 
when treated with tiotropium compared with placebo. 
In patients who did not discontinue anticholinergic therapy, 
the risk reduction was 21% with tiotropium compared with 
placebo. In a similar comparison, the risk for a hospitalized 
exacerbation was reduced by 15% and 21%, respectively. 
The reduced risk was also associated with reduced rates 
of exacerbations and hospitalized exacerbations, regard-
less of previous anticholinergic use. Thus, withdrawal of 
inhaled anticholinergics upon entry into tiotropium trials 
did not appear to influence the effect of tiotropium on the 
clinically important patient outcome of exacerbations of 
COPD. In addition, in the seven trials where the SGRQ was 
measured, tiotropium significantly reduced the SGRQ total 
score in both groups of patients.
Exacerbations are a significant component of the clinical 
course in COPD.15,16 Furthermore, as COPD progresses, 
exacerbations become more frequent.16 Some investigators 
have suggested that more frequent exacerbations are 
associated with more rapid decline of FEV
1
.17,18 Certainly, 
exacerbations have profound effects on quality of life.19 For 
example, SGRQ scores have been shown to be decreased 
(worsened) below baseline for up to six months following 
an exacerbation.20 Finally, exacerbations are associated 
with significant mortality.21 More widespread clinical use of 
tiotropium in COPD patients might predictably ameliorate the 
effects of recurrent exacerbations on the clinical course of the 
disease and impact the design of future clinical trials.
Recently, there have been increasing concerns about 
the effects of withdrawal of medications on the entry into 
clinical trials. van der Valk et al3 treated patients with 
inhaled fluticasone 1000 µg/day for four months and then 
randomized the patients to continue receiving fluticasone or 
to switch to placebo. During the subsequent six months of 
follow-up, 47% of patients in the fluticasone group developed 
a COPD exacerbation compared with 57% in the placebo 
group. Significant differences were seen in the HR for first 
exacerbation, as well as differences in health-related quality 
of life as measured by the SGRQ, which favored those 
patients continuing on fluticasone. However, the question 
arises as to whether this is a safety concern due to sudden 
withdrawal of a high dose of systemically absorbed inhaled 
corticosteroids or if the observations are surrogate measures 
of efficacy.
Suissa et al1 described methodological issues in thera-
peutic trials of COPD, and drew attention to the problem 
of medication withdrawal using inhaled corticosteroids 
prior to randomization as an example. In the case of the 
Towards a Revolution in COPD Health (TORCH) study, this 
phenomenon led in effect to two comparisons, ie, withdrawal 
of inhaled corticosteroids compared with continuation of 
inhaled corticosteroids in patients previously taking these 
agents, and introduction of inhaled corticosteroids compared 
with placebo in patients not previously taking inhaled 
corticosteroids. Suissa et al1 also analyzed data from the 
Canadian Optimal Therapy of COPD Trial22 and found that 
the HR (inhaled corticosteroids relative to bronchodilators 
Table 2 number of patients with at least one exacerbation by discontinuation of anticholinergics
Placebo  
(n = 5868)  
n (%)
Tiotropium  
(n = 6295)  
n (%)
Odds ratio  
(95% confidence  
interval)
P value
Discontinued 1187 (42.7) 1221 (39.9) 0.88 (0.80–0.93) 0.0223
not discontinued 1294 (41.9) 1154 (35.7) 0.77 (0.69–0.85) ,0.0001
Difference 0.0620
Notes: results are based on a logistic regression model with terms for treatment, subgroup, trial and treatment *subgroup interaction. The denominator for the percentages 
is the number of patients in each combination of subgroup and treatment: discontinued, n (placebo) = 2783, n (tiotropium) = 3063; not discontinued n (placebo) = 3085, 
n (tiotropium) = 3232.
Table 3 number of patients with at least one hospitalization by discontinuation of anticholinergics
Placebo  
(n = 5868)  
n (%)
Tiotropium  
(n = 6295)  
n (%)
Odds ratio  
(95% confidence  
interval)
P value
Discontinued 315 (11.3) 320 (10.4) 0.92 (0.78–1.09) 0.3173
not discontinued 255 (8.3) 215 (6.7) 0.79 (0.66–0.96) 0.0160
Difference 0.2473
Notes: results are based on a logistic regression model with terms for treatment, subgroup, trial and treatment *subgroup interaction. The denominator for the percentages 
is the number of patients in each combination of subgroup and treatment: discontinued: n (placebo) = 2783, n (tiotropium) = 3063; not discontinued: n (placebo) = 3085, 
n (tiotropium) = 3232.
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only) for the first exacerbation among previous inhaled 
corticosteroids users was 0.71 (95% CI 0.53–0.96), while 
among those not using inhaled corticosteroids prior to 
randomization, the HR (inhaled corticosteroids relative 
to bronchodilators only) was 1.11 (95% CI 0.69–1.79). 
In addition, the ratio for exacerbations in patients prior 
to discontinuing inhaled corticosteroids was 0.78 (95% 
CI 0.61–0.99) compared with 1.23 (95% CI 0.78–1.95) 
thereafter. These concerns prompted a detailed retrospective 
analysis of data from TORCH.23 In this paper, Keene et al 
argued that a negative binomial model was the best approach 
to statistical analysis of exacerbation rates and that a similar 
reduction in exacerbations could be calculated regardless of 
whether or not subjects had discontinued inhaled corticos-
teroids at randomization.
Suissa et al1 suggested in their paper that withdrawal 
of inhaled anticholinergic therapy might cause similar 
problems to those they described related to withdrawal of 
inhaled corticosteroids. However, our results clearly refute 
that suggestion. Furthermore, we have demonstrated a 
similar reduction in the number of exacerbations per patient 
year in those who continued and those who discontinued 
inhaled anticholinergic therapy upon randomization into 
these tiotropium clinical trials. This significant benefit 
argues that the clinical trial results, in terms of the difference 
between tiotropium and placebo, favor a positive effect 
from tiotropium rather than a negative effect from inhaled 
anticholinergic withdrawal in the placebo group.
As well as demonstrating that tiotropium reduced 
exacerbations regardless of changes in prior therapy, we were 
also able to demonstrate that tiotropium, when compared with 
placebo, improved health-related quality of life (as measured 
by SGRQ), regardless of whether or not patients had been 
taking inhaled anticholinergic therapy prior to randomization. 
The improvement in SGRQ was statistically significant for 
both the D and ND groups, although numerically greater 
for those patients who discontinued previous anticholinergic 
therapy. Such improvements are a predictable complement to 
the effect on exacerbations.
We can speculate why withdrawal of inhaled anticholinergic 
therapy does not affect the outcome of placebo-controlled 
clinical trials of tiotropium, whereas withdrawal of inhaled 
corticosteroids seems to be problematic. The effect of 
ipratropium, which is the short-acting anticholinergic taken by 
many patients prior to entry into the tiotropium trials, is well 
understood to be restricted to antimuscarinic smooth muscle 
relaxation and presumably wears off relatively quickly, 
although there is some evidence that the effects of extended 
therapy with ipratropium persist longer than the conventional 
6–8-hour duration of acute bronchodilation.24 Although 
considered a short-acting bronchodilator, ipratropium 
alone or in combination with albuterol has been shown to 
reduce exacerbations compared with albuterol alone.25 This 
observation suggests that one should consider whether a 
“rebound” effect (ie, an increase in exacerbation rate) might 
be a consequence of ipratropium withdrawal. In a study of 
nine subjects with mild asthma, Newcomb et al26 described 
a short-term increase in airway hyperresponsiveness to 
methacholine upon withdrawal of regular use of ipratropium, 
which could represent upregulation of muscarinic receptors 
on the surface of airway smooth muscle cells. However, 
these findings have not been replicated, and the current 
analysis demonstrates that a rebound worsening of COPD 
is unlikely to occur upon withdrawal of ipratropium. The 
corollary is not necessarily true for inhaled corticosteroids, 
because there are systemic effects of inhaled corticosteroids 
and both beneficial effects and adverse events are likely to 
occur over longer periods of time, which may also delay the 
onset of safety issues.
As with any meta-analysis, our study has certain 
 limitations.27 We acknowledge that this is a retrospective 
analysis and includes trials of different size and duration. 
However, the strengths of the study are the prospective 
nature of the clinical trials selected for the pooled analysis 
and the consistency of their entry criteria. Furthermore, these 
studies were rigorously conducted, randomized, double-
blind, controlled clinical trials that provided large numbers 
of patients, all of whom were included in the analysis.
Conclusion
In summary, we have demonstrated that tiotropium reduced 
exacerbations and hospitalizations in a large number of COPD 
patients, regardless of whether or not they discontinued 
inhaled anticholinergic therapy prior to randomization 
into the placebo-controlled clinical trials. These findings 
strengthen the validity of conclusions previously reported 
from these clinical trials that treatment with tiotropium 
reduces exacerbations, and that the beneficial effect is equally 
observed whether or not patients had previously received 
inhaled anticholinergic therapy.
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